

Table S1: Comparison of Idylla and Oncomine Pan Cancer results.

ID	Baseline		8 Weeks		PD		PD 3 Months	
	Idylla	NGS (AF%)	Idylla	NGS	Idylla	NGS	Idylla	NGS
01-0002	–	–	KRAS: p.G12S (3,9%); BRAF: p.V600E/D BRAF: p.V600D (1,8%)		–	–	–	–
01-0005	–	TP53: p.R273C (14,6%)	–	TP53: p.R273C (11,2%)	NRAS: p.Q61R/K	NRAS: p.Q61K (2,8%); TP53: p.R273C (7,8%)	–	–
01-0008	–	–	–	–	KRAS: p.G12C	KRAS: p.G12C (6,4%)	sample not available	
01-0010	KRAS: p.G12R	KRAS: p.G12R (1,8%)	–	–	–	FBXW7: p.R465C (1,5%)	sample not available	
01-0011	KRAS: p.G12A	KRAS: p.G12A (2,2%)	–	–	KRAS: p.G12A	KRAS: p.G12A (3%); TP53: p.R280I (2,5%)	KRAS: p.G12A	KRAS: p.G12A (3,8%); TP53: p.R280I (2,9%)
01-0014	KRAS: p.A59T/E/G	KRAS: p.A59T (5,4%)	–	–	KRAS: p.A59T/E/G	KRAS: p.A59T (4,4%)	Invalid	EGFR: p.S492R (0,4%)
01-0017	–	–	KRAS: p.G12A	KRAS: p.G12A (5,1%)	BRAF: p.V600E/D	BRAF: p.V600E (2,5%)	–	–
01-0019	KRAS: p.G12D	KRAS: p.G12D (1,9%)	KRAS: p.G12D	KRAS: p.G12D (2%)	KRAS: p.G12D	KRAS: p.G12D (2,5%)	sample not available	
01-0024	–	–	–	–	NRAS: p.Q61H	NRAS: p.Q61H (4,1%)	–	–
01-0027	–	–	–	–	KRAS: p.G12R	KRAS: p.G12R (3,4%)	–	–
01-0028	–	–	–	–	–	–	KRAS: p.G12V; NRAS: p.Q61H	KRAS: p.G12V (2,4%)
01-0033	–	–	NRAS: p.A59T	NRAS: p.A59T (3,4%)	–	–	–	–
01-0038	–	–	NRAS: p.G12A/V	NRAS: p.G12V (2,2%)	–	–	–	–
61-0001	–	–	sample not available		BRAF: p.V600E/D	BRAF: p.V600E (1,9%)	sample not available	
06-0002	–	TP53: p.R175H (5,4%)	sample not available		KRAS: p.A146P/T/V; BRAF: p.V600E/D	KRAS: p.A146T (1,5%); BRAF: p.V600E (3,2%); TP53: p.R175H (2,8%)	sample not available	
29-0001	BRAF: p.V600E/D	BRAF: p.V600E (4,7%)	BRAF: p.V600E/D	BRAF: p.V600E (5,7%)	the sample at week 8 coincided with PD		sample not available	
26-0002	–	–	–	–	BRAF: p.V600E/D	BRAF: p.V600E (2,6%)	–	–
33-0004	–	–	–	–	NRAS: p.Q61R/K; BRAF: p.V600E/D	NRAS: p.Q61K (4,8%); BRAF: p.V600D (2,6%)	sample not available	
57-0002	–	–	KRAS: p.A146T KRAS: p.A146P/T/V (3,1%)		–	–	–	–
57-0006	–	–	–	–	KRAS: p.G12C	KRAS: p.G12C (4,3%)	–	–

Table S2. mPFS observed between KRAS/NRAS/BRAF mutant versus wild type cases when considering patients mutant at baseline, at week 8, at progression or at any time-point.

Samples		N	MEDIAN PFS	P Value	Hazard Ratio (95% CI of Ratio)
T0	WT	31	7.250	0.5818	0.7625 (0.2904 to 2.002)
	MUT	6	7.060		
T8	WT	25	7.590	0.8401	1.090 (0.4724 to 2.514)
	MUT	7	6.670		
PD	WT	23	7.130	0.3892	1.346 (0.6844 to 2.647)
	MUT	13	7.710		
Any Time Point	WT	17	7.130	0.5476	1.230 (0.6269 to 2.412)
	MUT	20	7.470		